A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

Adrian Bot, Mark Ahn, Marnix Bosch, Dirk Brockstedt, Lisa H. Butterfield, Andrew Cornforth, Richard Harrop, W. M. Kast, Richard Koya, Francesco Marincola, Kim Margolin, Candice McCoy, Graham Pawelec, John Rothman, Teresa Ramirez-Montagut, Jeffrey Schlom, Pramod Srivastava, Sarah Wallis, Steffen Walter, Ena Wang & 1 others John Waslif

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

Original languageEnglish
Article number218
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 5 Nov 2012
Externally publishedYes

Fingerprint

Immunotherapy
Immune system
Sagittaria
Stem cells
Industry
Neoplasms
Immune System
Stem Cells
Research
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. / Bot, Adrian; Ahn, Mark; Bosch, Marnix; Brockstedt, Dirk; Butterfield, Lisa H.; Cornforth, Andrew; Harrop, Richard; Kast, W. M.; Koya, Richard; Marincola, Francesco; Margolin, Kim; McCoy, Candice; Pawelec, Graham; Rothman, John; Ramirez-Montagut, Teresa; Schlom, Jeffrey; Srivastava, Pramod; Wallis, Sarah; Walter, Steffen; Wang, Ena; Waslif, John.

In: Journal of Translational Medicine, Vol. 10, No. 1, 218, 05.11.2012.

Research output: Contribution to journalArticle

Bot, A, Ahn, M, Bosch, M, Brockstedt, D, Butterfield, LH, Cornforth, A, Harrop, R, Kast, WM, Koya, R, Marincola, F, Margolin, K, McCoy, C, Pawelec, G, Rothman, J, Ramirez-Montagut, T, Schlom, J, Srivastava, P, Wallis, S, Walter, S, Wang, E & Waslif, J 2012, 'A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies', Journal of Translational Medicine, vol. 10, no. 1, 218. https://doi.org/10.1186/1479-5876-10-218
Bot, Adrian ; Ahn, Mark ; Bosch, Marnix ; Brockstedt, Dirk ; Butterfield, Lisa H. ; Cornforth, Andrew ; Harrop, Richard ; Kast, W. M. ; Koya, Richard ; Marincola, Francesco ; Margolin, Kim ; McCoy, Candice ; Pawelec, Graham ; Rothman, John ; Ramirez-Montagut, Teresa ; Schlom, Jeffrey ; Srivastava, Pramod ; Wallis, Sarah ; Walter, Steffen ; Wang, Ena ; Waslif, John. / A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{73b457f14f11478881f51cf2b67a906c,
title = "A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies",
abstract = "While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.",
author = "Adrian Bot and Mark Ahn and Marnix Bosch and Dirk Brockstedt and Butterfield, {Lisa H.} and Andrew Cornforth and Richard Harrop and Kast, {W. M.} and Richard Koya and Francesco Marincola and Kim Margolin and Candice McCoy and Graham Pawelec and John Rothman and Teresa Ramirez-Montagut and Jeffrey Schlom and Pramod Srivastava and Sarah Wallis and Steffen Walter and Ena Wang and John Waslif",
year = "2012",
month = "11",
day = "5",
doi = "10.1186/1479-5876-10-218",
language = "English",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies

AU - Bot, Adrian

AU - Ahn, Mark

AU - Bosch, Marnix

AU - Brockstedt, Dirk

AU - Butterfield, Lisa H.

AU - Cornforth, Andrew

AU - Harrop, Richard

AU - Kast, W. M.

AU - Koya, Richard

AU - Marincola, Francesco

AU - Margolin, Kim

AU - McCoy, Candice

AU - Pawelec, Graham

AU - Rothman, John

AU - Ramirez-Montagut, Teresa

AU - Schlom, Jeffrey

AU - Srivastava, Pramod

AU - Wallis, Sarah

AU - Walter, Steffen

AU - Wang, Ena

AU - Waslif, John

PY - 2012/11/5

Y1 - 2012/11/5

N2 - While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

AB - While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84868242056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868242056&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-218

DO - 10.1186/1479-5876-10-218

M3 - Article

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 218

ER -